Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)
NCT ID: NCT01615874
Last Updated: 2022-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2013-01-31
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)
NCT01502371
Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)
NCT02741271
A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)
NCT01258803
Use of Montelukast to Treat Children With Mild to Moderate Acute Asthma
NCT00213252
Montelukast With Status Asthmaticus, Ages 6-18
NCT00494572
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MF/F MDI 50/10 mcg BID
MF/F Metered Dose Inhaler (MDI) 25/5 mcg
MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)
Rescue medication: short-acting beta-2 agonist (SABA) MDI
albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
Rescue medication: Prednisone/Prednisolone
Prednisone/Prednisolone for rescue medication, taken as directed
MF/F MDI 100/10 mcg BID
MF/F MDI 50/5 mcg
MF/F MDI 50/5 mcg, 2 inhalations BID
Rescue medication: short-acting beta-2 agonist (SABA) MDI
albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
Rescue medication: Prednisone/Prednisolone
Prednisone/Prednisolone for rescue medication, taken as directed
MF/F MDI 200/10 mcg BID
MF/F MDI 100/5 mcg
MF/F MDI 100/5 mcg, 2 inhalations BID
Rescue medication: short-acting beta-2 agonist (SABA) MDI
albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
Rescue medication: Prednisone/Prednisolone
Prednisone/Prednisolone for rescue medication, taken as directed
BDP HFA 160 mcg BID
BDP hydrofluoroalkane (HFA) 80 mcg
BDP HFA 80 mcg, 2 inhalations BID
Rescue medication: short-acting beta-2 agonist (SABA) MDI
albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
Rescue medication: Prednisone/Prednisolone
Prednisone/Prednisolone for rescue medication, taken as directed
Montelukast 5 mg QD (4 mg QD for 5-year-olds)
Montelukast tablets 5 mg (4 mg for children 5 years of age)
Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age
OR
Montelukast chewable tablets 4 mg QD for children 5 years of age
Rescue medication: short-acting beta-2 agonist (SABA) MDI
albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
Rescue medication: Prednisone/Prednisolone
Prednisone/Prednisolone for rescue medication, taken as directed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MF/F Metered Dose Inhaler (MDI) 25/5 mcg
MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)
MF/F MDI 50/5 mcg
MF/F MDI 50/5 mcg, 2 inhalations BID
MF/F MDI 100/5 mcg
MF/F MDI 100/5 mcg, 2 inhalations BID
BDP hydrofluoroalkane (HFA) 80 mcg
BDP HFA 80 mcg, 2 inhalations BID
Montelukast tablets 5 mg (4 mg for children 5 years of age)
Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age
OR
Montelukast chewable tablets 4 mg QD for children 5 years of age
Rescue medication: short-acting beta-2 agonist (SABA) MDI
albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
Rescue medication: Prednisone/Prednisolone
Prednisone/Prednisolone for rescue medication, taken as directed
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* body weight ≥18 kg
* able to discontinue prescribed inhaled corticosteroid (ICS) or ICS combined with long-acting beta-agonist (LABA) before starting study medication
* use of a low or medium daily dose of ICS (either alone or in combination with a LABA) with no use of oral corticosteroids within 3 months prior to Screening Visit
* stable asthma regimen (daily dose unchanged) for ≥2 weeks prior to Screening Visit
* documented positive responsiveness to bronchodilators
* ability to use a peak flow meter correctly and to perform spirometry and PEF measurements
* ability to use an inhaler correctly
* consent/assent for the trial and for pharmacogenetic testing (Note: If unwilling to consent/assent for pharmacogenetic testing, inclusion in the study is still allowed, but no pharmacogenetic samples will be obtained.)
Exclusion Criteria
* treatment in the emergency room (for a severe asthma exacerbation requiring systemic corticosteroid treatment) or hospitalization for management of airway obstruction within 3 months prior to Screening Visit
* ever required ventilator support for respiratory failure secondary to asthma
* upper or lower respiratory tract infection (viral or bacterial) within 2 weeks prior to Screening Visit
* clinically significant abnormal vital sign
* evidence of oropharyngeal candidiasis
* history of clinically significant renal, hepatic, cardiovascular, metabolic, neurologic, hematologic, ophthalmologic, respiratory, gastrointestinal, cerebrovascular, or other significant medical illness or disorder that may interfere with study participation. Specific examples include but are not limited to insulin-dependent diabetes, active hepatitis, cardiovascular disease including hypertension, or conditions that may interfere with respiratory function such as, bronchiectasis, and cystic fibrosis
* allergy to or intolerance of corticoids, beta-2 agonists, montelukast or any of the inactive ingredients in the medications used in this study
* participation in this same study at another study site
* previous randomization into this study
* participation in another investigational study for the duration of this study
* use of any investigational drug within one month prior to Screening Visit
* previous participation in a study with MF/F or montelukast
* direct association with or family member of one of the investigators or study staff
* sibling of a participant in this study
5 Years
11 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Organon and Co
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-010108-27
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
P05574
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.